DE60239146D1 - Neue kristalline verbindung - Google Patents

Neue kristalline verbindung

Info

Publication number
DE60239146D1
DE60239146D1 DE60239146T DE60239146T DE60239146D1 DE 60239146 D1 DE60239146 D1 DE 60239146D1 DE 60239146 T DE60239146 T DE 60239146T DE 60239146 T DE60239146 T DE 60239146T DE 60239146 D1 DE60239146 D1 DE 60239146D1
Authority
DE
Germany
Prior art keywords
connection
new crystals
crystals
new
crystals connection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239146T
Other languages
English (en)
Inventor
Mark Edward Flanagan
Zheng Jane Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23326961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60239146(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60239146D1 publication Critical patent/DE60239146D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60239146T 2001-12-06 2002-11-25 Neue kristalline verbindung Expired - Lifetime DE60239146D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33898401P 2001-12-06 2001-12-06
PCT/IB2002/004948 WO2003048162A1 (en) 2001-12-06 2002-11-25 Novel crystalline compound

Publications (1)

Publication Number Publication Date
DE60239146D1 true DE60239146D1 (de) 2011-03-24

Family

ID=23326961

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239146T Expired - Lifetime DE60239146D1 (de) 2001-12-06 2002-11-25 Neue kristalline verbindung

Country Status (30)

Country Link
US (2) US6965027B2 (de)
EP (1) EP1451192B1 (de)
JP (1) JP4201135B2 (de)
KR (1) KR100691590B1 (de)
CN (1) CN1325498C (de)
AR (1) AR037635A1 (de)
AT (1) ATE497962T1 (de)
AU (1) AU2002348857B2 (de)
BR (1) BR0214761A (de)
CA (1) CA2469350C (de)
CO (1) CO5580780A2 (de)
CY (1) CY1111311T1 (de)
DE (1) DE60239146D1 (de)
DK (1) DK1451192T3 (de)
ES (1) ES2357942T3 (de)
GT (1) GT200200234A (de)
HK (1) HK1070653A1 (de)
HN (1) HN2002000349A (de)
IL (1) IL161914A0 (de)
MX (1) MXPA04005401A (de)
NO (1) NO20042721L (de)
NZ (1) NZ532366A (de)
PA (1) PA8560201A1 (de)
PE (1) PE20030807A1 (de)
PL (1) PL221493B1 (de)
RU (1) RU2315052C2 (de)
TW (1) TW200300690A (de)
UY (1) UY27567A1 (de)
WO (1) WO2003048162A1 (de)
ZA (1) ZA200404270B (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
AU777911B2 (en) 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2337782T3 (es) 2002-07-29 2010-04-29 Rigel Pharmaceuticals, Inc. Metodos para tratar o prevenir enfermedades autoinmunitarias con compuestos de 2,4-pirimidindiamina.
EP1572213A1 (de) * 2002-11-26 2005-09-14 Pfizer Products Inc. Verfahren zur behandlung dertransplantatabstossung
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
MX2007006204A (es) * 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
CN105348203B (zh) 2005-06-08 2018-09-18 里格尔药品股份有限公司 抑制jak途径的组合物和方法
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
EP2251341A1 (de) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclische Januskinase-3-Inhibitoren
ATE540952T1 (de) 2005-07-29 2012-01-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidinderivate, ihre zwischenprodukte und synthese
EP2270014A1 (de) 2005-09-22 2011-01-05 Incyte Corporation Azepinhemmer von Janus-Kinasen
PT2348023E (pt) 2005-12-13 2015-09-15 Incyte Corp Pirrolo[2,3-b] pirimidinas e pirrolo[2,3-b]piridinas substituídas com heteroarilo como inibidores de janus quinase
JP2009528295A (ja) 2006-02-24 2009-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｊａｋ経路の阻害のための組成物および方法
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
WO2008079965A1 (en) 2006-12-22 2008-07-03 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
ME00960B (me) 2007-06-13 2012-06-20 Incyte Corp Soli inhibitora janus kinaze, (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrila
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
NZ582188A (en) 2007-07-11 2012-03-30 Pfizer Pharmaceutical compositions and methods of treating dry eye disorders
US20100267720A1 (en) * 2007-07-30 2010-10-21 Astrazeneca Ab Crystalline Forms of 2-Hydroxy-3- [5- (Morpholin- 4- Ylmethyl) Pyridin-2-YL] IH- Indole- 5 -Carbonitrile Citrate
ES2617622T3 (es) 2008-02-15 2017-06-19 Rigel Pharmaceuticals, Inc. Compuestos de pirimidin-2-amina y su uso como inhibidores de JAK cinasas
EP2288610B8 (de) 2008-03-11 2016-10-12 Incyte Holdings Corporation Azetidin- und cyclobutanderivate als jak-inhibitoren
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
NZ589315A (en) 2008-04-16 2012-11-30 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
PT2384326E (pt) 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
US20100189788A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline base formulation
ES2552805T3 (es) 2009-04-20 2015-12-02 Auspex Pharmaceuticals, Llc Inhibidores piperidínicos de la cinasa Janus 3
AR076920A1 (es) 2009-05-22 2011-07-20 Incyte Corp 3-(4-(7h-pirrolo(2,3-d)pirimidin-4-il)-1h-pirazol-1-il)octano-o heptano--nitrilo como inhibidores de jak
TW201100429A (en) 2009-05-22 2011-01-01 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011028685A1 (en) 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
ES2435491T3 (es) 2009-10-09 2013-12-19 Incyte Corporation Derivados de hidroxilo, ceto y glucurónido de 3-(4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciclopentilpropanonitrilo
PL2545045T3 (pl) 2010-03-10 2016-08-31 Incyte Holdings Corp Pochodne piperydyn-4-yloazetydyny jako inhibitory JAK1
US20110288107A1 (en) 2010-05-21 2011-11-24 Bhavnish Parikh Topical formulation for a jak inhibitor
EP2975027A1 (de) 2010-11-01 2016-01-20 Portola Pharmaceuticals, Inc. Nicotinamide als jak-kinasemodulatoren
KR20140019300A (ko) 2010-11-19 2014-02-14 인사이트 코포레이션 Ｊａｋ 억제제로서 사이클로부틸 치환된 피롤로피리딘 및 피롤로피리미딘 유도체
EP2640725B1 (de) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclensubstituierte pyrrolopyridine und pyrrolopyrimidine als jak-inhibitoren
EP2481411A1 (de) * 2011-01-27 2012-08-01 Ratiopharm GmbH Orale Dosierformen für modifizierte Freisetzung mit dem JAK3-Hemmer tasocitinib
EP2481397A1 (de) 2011-01-27 2012-08-01 Ratiopharm GmbH Pharmazeutische Zusammensetzungen mit Tasocitinib
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
EP2691395B1 (de) 2011-03-28 2017-08-30 ratiopharm GmbH Verfahren zur herstellung von salzen von tofacitinib
KR101593768B1 (ko) 2011-04-08 2016-02-12 화이자 인코포레이티드 토파시티닙의 결정질 형태 및 비결정질 형태, 및 토파시티닙 및 침투 증진제를 포함하는 제약 조성물
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
JP2014521725A (ja) 2011-08-10 2014-08-28 ノバルティス・ファルマ・アクチェンゲゼルシャフト ＪＡＫＰＩ３Ｋ／ｍＴＯＲ併用療法
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA3094793A1 (en) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
BR112014013224B1 (pt) 2011-11-30 2023-03-07 Emory University Inibidores de jak antivirais úteis no tratamento ou prevenção de infecções retrovirais e outras infecções virais
WO2013090490A1 (en) 2011-12-15 2013-06-20 Ratiopharm Gmbh Tofacitinib salts
WO2013173506A2 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2014058921A2 (en) 2012-10-08 2014-04-17 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
PT2919766T (pt) 2012-11-15 2021-07-29 Incyte Corp Formas farmacêuticas de ruxolitinib de libertação controlada
WO2014097150A1 (en) 2012-12-17 2014-06-26 Ranbaxy Laboratories Limited Process for the preparation of tofacitinib and intermediates thereof
EP2938616A4 (de) * 2012-12-28 2016-06-15 Glenmark Pharmaceuticals Ltd Verarbeitungsverfahren zur herstellung von tofacitinib und zwischenprodukten davon
CN103073552B (zh) * 2013-02-05 2015-08-12 华润赛科药业有限责任公司 一种无定型枸橼酸托法替尼的制备方法
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2014174073A1 (en) 2013-04-26 2014-10-30 Sandoz Ag Sustained release formulations of tofacitinib
WO2014195978A2 (en) * 2013-06-05 2014-12-11 Msn Laboratories Limited PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CN104341422A (zh) * 2013-07-26 2015-02-11 重庆医药工业研究院有限责任公司 托菲替尼的中间体及其制备方法
CN116036089A (zh) 2013-08-07 2023-05-02 因赛特控股公司 Jak1抑制剂的持续释放剂型
CN104447751A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼化合物
CN104447752A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 一种托法替尼水合物及其制备方法
CN104292231B (zh) * 2013-09-17 2016-11-30 广东东阳光药业有限公司 一种枸橼酸托法替尼的制备方法
CN105873931B (zh) * 2013-10-08 2018-10-16 广东东阳光药业有限公司 托法替布柠檬酸盐
CN103585126A (zh) * 2013-11-18 2014-02-19 南京艾德凯腾生物医药有限责任公司 一种托法替尼组合物及制备方法
HUE042911T2 (hu) * 2013-12-09 2019-07-29 Unichem Lab Ltd Javított eljárás a (3R,4R)-(1-benzil-4-metil-piperidin-3-il)-metilamin elõállítására
CN104774206A (zh) * 2014-01-14 2015-07-15 江苏柯菲平医药股份有限公司 制备枸橼酸托伐替尼晶型a的新方法
CA2881262A1 (en) * 2014-02-06 2015-08-06 Prabhudas Bodhuri Solid forms of tofacitinib salts
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN104387392B (zh) * 2014-08-22 2016-09-28 中孚药业股份有限公司 制备托法替布的方法
EP3328360A4 (de) * 2015-07-27 2019-01-02 Unichem Laboratories Limited Im mund zerfallende tofacitinib-tabletten
CN105348287A (zh) * 2015-11-30 2016-02-24 宁波立华制药有限公司 一种枸橼酸托法替布的新型合成工艺
US20190083609A1 (en) 2016-01-18 2019-03-21 Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) Tofacitinib as vaccination immune modulator
US10774094B2 (en) * 2016-11-23 2020-09-15 Wuxi Fortune Pharmaceutical Co., Ltd Crystal forms and salt forms of 7h-pyrrolo[2,3-d]pyrimidine compounds and preparation method thereof
WO2018172821A1 (en) * 2017-03-23 2018-09-27 Phalanx Labs Private Limited Novel tofacitinib addition salts and process for the preparation thereof
CN106967072B (zh) * 2017-04-12 2019-05-03 山东裕欣药业有限公司 一种枸橼酸托法替布晶型化合物及其制备方法
CN109293682A (zh) * 2017-07-25 2019-02-01 重庆医药工业研究院有限责任公司 一种托法替布杂质及其制备方法
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
LT3746429T (lt) 2018-01-30 2022-05-10 Incyte Corporation (1-(3-fluor-2-(trifluormetil)izonikotinil)piperidin-4-ono) gamybos būdai
WO2019182322A1 (ko) * 2018-03-20 2019-09-26 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
CN108484607A (zh) * 2018-03-26 2018-09-04 山东科兴生物制品有限公司 枸橼酸托法替布的新型制备方法
FI3773593T3 (fi) 2018-03-30 2024-06-18 Incyte Corp Hidradenitis suppurativan hoito jak-estäjiä käyttäen
WO2019213562A1 (en) 2018-05-03 2019-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
CN109516991B (zh) * 2018-12-29 2020-08-07 山东罗欣药业集团股份有限公司 一种枸橼酸托法替尼晶型化合物及其制备方法
KR20230031981A (ko) 2019-05-14 2023-03-07 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
KR102209701B1 (ko) 2019-08-16 2021-01-29 유니셀랩 주식회사 토파시티닙의 신규한 결정형 형태 및 이의 제조방법
KR20220101150A (ko) 2019-11-14 2022-07-19 화이자 인코포레이티드 1-(((2s,3s,4s)-3-에틸-4-플루오로-5-옥소피롤리딘-2-일)메톡시)-7-메톡시이소퀴놀린-6-카복사마이드 조합물 및 경구 투여 형태
BR112022020020A2 (pt) 2020-04-04 2022-11-22 Pfizer Métodos de tratamento da doença do coronavírus 2019
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021287998A1 (en) 2020-06-11 2023-02-02 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4180042A1 (de) 2021-11-15 2023-05-17 Sanovel Ilac Sanayi Ve Ticaret A.S. Filmbeschichtete tablette mit mikronisiertem tofacitinib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) * 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
DE59500788D1 (de) * 1994-05-03 1997-11-20 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
AU720429B2 (en) * 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
EP0972197A1 (de) * 1997-03-24 2000-01-19 PHARMACIA & UPJOHN COMPANY Verfahren zur identifizierung von jak2-cytokinrezeptor bindungsinhibitoren
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
EP1087970B1 (de) 1998-06-19 2004-04-28 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidin-verbindungen
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
AU777911B2 (en) * 1999-12-10 2004-11-04 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GT200200234A (es) * 2001-12-06 2003-06-27 Compuestos cristalinos novedosos

Also Published As

Publication number Publication date
PA8560201A1 (es) 2003-12-10
IL161914A0 (en) 2005-11-20
TW200300690A (en) 2003-06-16
AU2002348857B2 (en) 2008-12-04
CN1596257A (zh) 2005-03-16
EP1451192B1 (de) 2011-02-09
MXPA04005401A (es) 2004-10-11
US20030130292A1 (en) 2003-07-10
DK1451192T3 (da) 2011-04-04
BR0214761A (pt) 2004-11-09
NZ532366A (en) 2006-11-30
WO2003048162A1 (en) 2003-06-12
HN2002000349A (es) 2003-08-20
PE20030807A1 (es) 2003-09-22
PL221493B1 (pl) 2016-04-29
JP2005511696A (ja) 2005-04-28
JP4201135B2 (ja) 2008-12-24
ES2357942T3 (es) 2011-05-04
NO20042721L (no) 2004-06-28
GT200200234A (es) 2003-06-27
KR20050044691A (ko) 2005-05-12
HK1070653A1 (en) 2005-06-24
ATE497962T1 (de) 2011-02-15
CN1325498C (zh) 2007-07-11
KR100691590B1 (ko) 2007-03-09
ZA200404270B (en) 2005-10-26
CO5580780A2 (es) 2005-11-30
AU2002348857A1 (en) 2003-06-17
CA2469350C (en) 2009-09-29
AR037635A1 (es) 2004-11-17
EP1451192A1 (de) 2004-09-01
US7803805B2 (en) 2010-09-28
RU2004117088A (ru) 2005-03-27
US20050159434A1 (en) 2005-07-21
RU2315052C2 (ru) 2008-01-20
US6965027B2 (en) 2005-11-15
CA2469350A1 (en) 2003-06-12
UY27567A1 (es) 2003-07-31
PL370297A1 (en) 2005-05-16
CY1111311T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
DE60239146D1 (de) Neue kristalline verbindung
DK1671949T3 (da) Substituerede pyridinylaminer
NO20040084L (no) Peptid-baserte forbindelser
IS6971A (is) Ný efnasambönd
DE50206892D1 (de) Substituierte imidazotriazinone
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
IS2523B (is) Turn vindorkuvers
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
FI20011507A0 (fi) Uusia yhdisteitä
ATE232273T1 (de) Anschlusselement
ATA6842001A (de) Tank
FR2822519B1 (fr) Raccord pour tuyau
DE60211574D1 (de) Seriendruckgerät
DE50309081D1 (de) Neue diketopyrrolopyrrolpigmente
DE60217710D1 (de) Neue formulierung
ATA5002002A (de) Vibrator
ITMI20011758A1 (it) Ligandi
FI20010477A0 (fi) Suodatinrakenne
ATE405973T1 (de) Steckverbindung
DE60216967D1 (de) Substituierte cyclohexanderivate
DE60233952D1 (de) Neue serinprotease
ES1049292Y (es) Mazo solador
UA5581S (uk) Автоцистерна
NO20011529D0 (no) Væske-adskiller
UA5710S (uk) Каністра